Biohaven .(US:BHVN) Prnewswireยท2025-07-16 04:56Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations - The lawsuit claims that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole as a treatment for SCA [2]. - It is also alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The revelations from the lawsuit are expected to have a significant negative impact on Biohaven's business and financial condition [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].